PMID- 11305152
OWN - NLM
STAT- MEDLINE
DCOM- 20010517
LR  - 20131121
IS  - 0040-5930 (Print)
IS  - 0040-5930 (Linking)
VI  - 58
IP  - 3
DP  - 2001 Mar
TI  - [Long-term results of conservative management of reflux esophagitis].
PG  - 146-50
AB  - Reflux esophagitis is a frequent and chronic disease. Impairment of the quality 
      of life by the reflux symptoms and the risk of complications are the most 
      important indications for a long-term treatment. The base of the treatment of 
      reflux esophagitis is the inhibition of the gastric acid secretion with proton 
      pump inhibitors (PPI) or by H2-receptor antagonist. In general, PPI's are more 
      efficient in the treatment of refluxesophagitis as compared to H2-receptor 
      antagonists blockers regarding the relieve of symptoms and the healing of erosive 
      esophageal lesions. The use of an antacids and procinetics in the long-term 
      treatment is not indicated. The treatment strategy depends on the severity of the 
      symptoms and the esophageal lesions. Patient with mild esophagitis can be treated 
      either with H2-receptor antagonists or with PPI's on demand or continuous. In the 
      case of severe esophagitis, a long-term treatment with PPI's is indicated to 
      avoid complications. Recurrence of esophagitis during a long-term therapy should 
      be treated by PPI's. After healing the long-term treatment should be adapted 
      either by increasing the given dose of the medicament or by a switch to more 
      effective medicaments in acid suppression.
FAU - Viani, F
AU  - Viani F
AD  - Abteilung fur Gastroenterologie, CHUV, Lausanne.
FAU - Dorta, G
AU  - Dorta G
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Langzeitergebnisse der konservativen Behandlung der Refluxosophagitis.
PL  - Switzerland
TA  - Ther Umsch
JT  - Therapeutische Umschau. Revue therapeutique
JID - 0407224
RN  - 0 (Anti-Ulcer Agents)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - Age Factors
MH  - Anti-Ulcer Agents/adverse effects/*therapeutic use
MH  - Diet
MH  - Drug Therapy, Combination
MH  - Esophagitis, Peptic/complications/diet therapy/*drug therapy
MH  - Helicobacter Infections/*complications
MH  - Humans
MH  - Omeprazole/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Time Factors
MH  - Treatment Outcome
RF  - 23
EDAT- 2001/04/18 10:00
MHDA- 2001/05/18 10:01
CRDT- 2001/04/18 10:00
PHST- 2001/04/18 10:00 [pubmed]
PHST- 2001/05/18 10:01 [medline]
PHST- 2001/04/18 10:00 [entrez]
AID - 10.1024/0040-5930.58.3.146 [doi]
PST - ppublish
SO  - Ther Umsch. 2001 Mar;58(3):146-50. doi: 10.1024/0040-5930.58.3.146.